These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26254144)

  • 41. [The effect of neuroleptics in a attempt at understanding the vulnerability to schizophrenia].
    Meurice E
    Acta Psychiatr Belg; 1992; 92(6):339-54. PubMed ID: 1364282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Microglial hypothesis of schizophrenia].
    Kanba S; Kato T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Feb; 34(1):11-3. PubMed ID: 25069267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs.
    Newell KA
    Future Med Chem; 2013 Sep; 5(13):1471-4. PubMed ID: 24024939
    [No Abstract]   [Full Text] [Related]  

  • 44. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment.
    Snitz BE; MacDonald A; Cohen JD; Cho RY; Becker T; Carter CS
    Am J Psychiatry; 2005 Dec; 162(12):2322-9. PubMed ID: 16330597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relation between weight gain and clinical improvement: is there a metabolic threshold for second generation antipsychotics?
    Sharma E; Rao NP; Venkatasubramanian G; Behere RV; Varambally S; Sivakumar PT; Gangadhar BN
    Psychiatry Res; 2011 Mar; 186(1):155. PubMed ID: 20691482
    [No Abstract]   [Full Text] [Related]  

  • 46. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.
    Foussias G; Siddiqui I; Fervaha G; Agid O; Remington G
    J Psychopharmacol; 2015 Feb; 29(2):116-26. PubMed ID: 25516370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)?
    Schmidt-Hansen M; Le Pelley M
    Cogn Neuropsychiatry; 2012 Nov; 17(6):473-505. PubMed ID: 22443090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
    Marino MJ; Knutsen LJ; Williams M
    J Med Chem; 2008 Mar; 51(5):1077-107. PubMed ID: 18198826
    [No Abstract]   [Full Text] [Related]  

  • 49. No amygdala attenuation in schizophrenic patients treated with atypical antipsychotics.
    Sachs G; Moser E; Katschnig H; Gur RC; Gur RE; Erfurth A
    Psychiatry Res; 2012 May; 202(2):168-71. PubMed ID: 22703618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
    Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML
    Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics of antipsychotic treatment in schizophrenia.
    Pouget JG; Müller DJ
    Methods Mol Biol; 2014; 1175():557-87. PubMed ID: 25150876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The development of new drugs for the treatment of schizophrenia.
    Cookson J
    Br J Hosp Med; 1987 Dec; 38(6):542-8. PubMed ID: 2893648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Restoring GABAergic signaling and neuronal synchrony in schizophrenia.
    Akbarian S
    Am J Psychiatry; 2008 Dec; 165(12):1507-9. PubMed ID: 19047328
    [No Abstract]   [Full Text] [Related]  

  • 54. [Life environment, healing and treatment with neuroleptics in schizophrenia].
    Cullberg J
    Lakartidningen; 1987 Aug; 84(35):2691-5. PubMed ID: 2889859
    [No Abstract]   [Full Text] [Related]  

  • 55. Iloperidone (Fanapt)--another second-generation antipsychotic.
    Med Lett Drugs Ther; 2010 Feb; 52(1332):13-4; quiz 17. PubMed ID: 20208474
    [No Abstract]   [Full Text] [Related]  

  • 56. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia.
    Jhamnani K; Shivakumar V; Kalmady S; Rao NP; Venkatasubramanian G
    J Neuropsychiatry Clin Neurosci; 2013; 25(1):E06-7. PubMed ID: 23487204
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical News.
    Buckley PF
    Clin Schizophr Relat Psychoses; 2017; 11(3):129-132. PubMed ID: 29035102
    [No Abstract]   [Full Text] [Related]  

  • 58. Microglia and schizophrenia: where next?
    Notter T; Meyer U
    Mol Psychiatry; 2017 Jun; 22(6):788-789. PubMed ID: 28348384
    [No Abstract]   [Full Text] [Related]  

  • 59. Inflammatory Markers in Recent Onset Psychosis and Chronic Schizophrenia.
    Dickerson F; Stallings C; Origoni A; Schroeder J; Katsafanas E; Schweinfurth L; Savage C; Khushalani S; Yolken R
    Schizophr Bull; 2016 Jan; 42(1):134-41. PubMed ID: 26294704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional genomics indicate that schizophrenia may be an adult vascular-ischemic disorder.
    Moises HW; Wollschläger D; Binder H
    Transl Psychiatry; 2015 Aug; 5(8):e616. PubMed ID: 26261884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.